US Phase III clearance moves Green Cross' Factor VIII closer to global market
This article was originally published in Scrip
Executive Summary
Green Cross is looking to broaden the geographical horizons for its recombinant coagulation Factor VIII product GreenGene F (beroctocog alfa), which it views as a key growth product over the mid-term period.